MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced positive top-line results from its Phase II clinical trial involving the investigational antibacterial drug JNJ-Q2 for the treatment of acute bacterial skin and skin structure infections or ABSSSI1.
